Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Deparment of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
PLoS One. 2023 Mar 30;18(3):e0272682. doi: 10.1371/journal.pone.0272682. eCollection 2023.
The immunomodulatory effects of vitamin D are widely recognized and a few studies have been conducted to determine its utility in the treatment of tuberculosis, with mixed results. This study was conducted to see if vitamin D supplementation in patients with active pulmonary tuberculosis (PTB) in the Indian population contributed to sputum smear and culture conversion as well as the prevention of relapse.
This randomized double-blind placebo-controlled trial was conducted in three sites in India. HIV negative participants aged 15-60 years with sputum smear positive PTB were recruited according to the Revised National Tuberculosis Control Program guidelines and were randomly assigned (1:1) to receive standard anti-tubercular treatment (ATT) with either supplemental dose of oral vitamin D3 (60,000 IU/sachet weekly for first two months, fortnightly for next four months followed by monthly for the next 18 months) or placebo with same schedule. The primary outcome was relapse of PTB and secondary outcomes were time to conversion of sputum smear and sputum culture.
A total of 846 participants were enrolled between February 1, 2017 to February 27, 2021, and randomly assigned to receive either 60,000 IU vitamin D3 (n = 424) or placebo (n = 422) along with standard ATT. Among the 697 who were cured of PTB, relapse occurred in 14 participants from the vitamin D group and 19 participants from the placebo group (hazard risk ratio 0.68, 95%CI 0.34 to 1.37, log rank p value 0.29). Similarly, no statistically significant difference was seen in time to sputum smear and sputum culture conversion between both groups. Five patients died each in vitamin D and placebo groups, but none of the deaths were attributable to the study intervention. Serum levels of vitamin D were significantly raised in the vitamin D group as compared to the placebo group, with other blood parameters not showing any significant difference between groups.
The study reveals that vitamin D supplementation does not seem to have any beneficial effect in the treatment of PTB in terms to the prevention of relapse and time to sputum smear and culture conversion.
CTRI/2021/02/030977 (ICMR, Clinical trial registry-India).
维生素 D 的免疫调节作用已得到广泛认可,已有一些研究旨在确定其在治疗结核病中的效用,但结果喜忧参半。本研究旨在观察在印度人群中,补充维生素 D 是否有助于痰涂片和培养转化,以及预防复发。
这是一项在印度三个地点进行的随机、双盲、安慰剂对照试验。按照修订后的国家结核病控制规划指南,招募了年龄在 15-60 岁之间、痰涂片阳性肺结核的 HIV 阴性参与者,并根据随机分配(1:1)接受标准抗结核治疗(ATT)加或不加口服维生素 D3 补充剂量(前两个月每周 60,000IU/袋,接下来四个月每两周一次,然后接下来 18 个月每月一次)或相同方案的安慰剂。主要结局是肺结核复发,次要结局是痰涂片和痰培养转化的时间。
2017 年 2 月 1 日至 2021 年 2 月 27 日期间,共招募了 846 名参与者,并随机分配接受 60,000IU 维生素 D3(n=424)或安慰剂(n=422)加标准 ATT。在 697 名治愈肺结核的患者中,维生素 D 组有 14 名患者和安慰剂组有 19 名患者复发(风险比 0.68,95%CI 0.34 至 1.37,对数秩检验 p 值 0.29)。同样,两组间痰涂片和痰培养转化时间也无统计学差异。维生素 D 组和安慰剂组各有 5 名患者死亡,但无死亡归因于研究干预。与安慰剂组相比,维生素 D 组的血清维生素 D 水平显著升高,而两组间其他血液参数无显著差异。
本研究表明,补充维生素 D 似乎对预防肺结核复发以及痰涂片和培养转化时间没有任何有益作用。
CTRI/2021/02/030977(印度临床试验注册中心)。